The most common mechanism of RIPK2 in malignant tumours may occur through the NF-κB signalling pathway, and the NF-κB signalling pathway is closely related to tumour occurrence and development [8] as well as chemotherapy drug sensitivity [48], radiotherapy sensitivity [49], targeted therapy sensitivity [50] and immunotherapy [51]. The gene discussed is NFKB1; the disease is cancer.